Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the United States

François Laliberté, Monika Raut, Xiaoqin Yang, Guillaume Germain, MSc, Shuvayu S Sen, Sean D. MacKnight, Kaushal D Desai, Mei Sheng Duh

Blood (2019) 134 (Supplement_1): 4720.

https://doi.org/10.1182/blood-2019-128876

Published: 2019

Journal Articles

Concomitant Acute Promyelocytic Leukemia and Chronic Lymphocytic Leukemia: Molecularly Two Distinct Diseases

Jingdong Su, MD, Hazem E. El-Osta, MD, Reinhold Munker, MD, Glenn M. Mills, MD, Srinivas S. Devarakonda, MD

Blood (2015) 126 (23): 4904.

https://doi.org/10.1182/blood.V126.23.4904.4904

Published: 2015

Journal Articles

Two Cases of Pediatric Acute Lymphoblastic Leukemia with t(5;14): a Challenging and Unique Entity

Renee-Pier Fortin-Boudreault, MD, Elaine W. Leung, MDFRCPC, Mylene Bassal, MDM

Blood (2015) 126 (23): 4870.

https://doi.org/10.1182/blood.V126.23.4870.4870

Published: 2015

Journal Articles

Cardiac Safety of NEPA, a Fixed-Dose Antiemetic Combination, Administered Prior to Anthracycline-Based Chemotherapy

Meinolf Karthaus, MD, Matti Aapro, MD, Giada Rizzi, M.Sc., Marco Palmas, MD

Blood (2014) 124 (21): 4821.

https://doi.org/10.1182/blood.V124.21.4821.4821

Published: 2014

Journal Articles

Comparative Effectiveness and Safety Of Pathogen Inactivated (Amotosalen-UVA) and Conventional Plasma For Treatment Of Auto-Immmune Thrombotic Thrombocytopenic Purpura (TTP): A 15-Year Retrospective Review

Raoul Herbrecht, MD, Mario Ojeda-Uribe, MD, Daniel Kientz, MD, Alain Bohbot, MD, Olivier Hinschberger, MD, Cecile Fohrer, MD, Kun-Lun Liu, MD, Emilie Remy, Christine Ernst, MD, Laurence Corash, MD, Jean-Pierre Cazenave, MD, PhD

Blood (2013) 122 (21): 4820.

https://doi.org/10.1182/blood.V122.21.4820.4820

Published: 2013

Journal Articles

Evaluation of the Acute Coronary Syndrome Safety Profile of Dabigatran Etexilate in Patients Undergoing Major Orthopaedic Surgery: Findings From Four Phase III Trials

Bengt I Eriksson, MD, John J Smith, MD, PhD, Joseph Caprini, MD, Stefan Hantel, PhD, Andreas Clemens, MD, Martin Feuring, MD, Gregory W Barsness, MD

Blood (2011) 118 (21): 2309.

https://doi.org/10.1182/blood.V118.21.2309.2309

Published: 2011

Journal Articles

Comparison of Adverse Drug Reactions for Patients Treated with Tyrosine Kinase Inhibitors: Data Mining of the Public Version of the FDA Adverse Event Reporting System (AERS)

Tetsuya Tanimoto, MD, Yasuo Oshima, MD, PhD, FACP, Koichiro Yuji, M.D., Ph.D., Masahiro Kami, MD, PhD

Blood (2011) 118 (21): 1698.

https://doi.org/10.1182/blood.V118.21.1698.1698

Published: 2011

Journal Articles

Fas and Fas Ligand Expression In Children with Acute Lymphoblastic Leukemia, Benign Hematological Diseases and Solid Tumors

Eftichia Stiakaki, MD, PhD, Georgia Martimianaki, Maria Kaparou, MD, Chryssoula Perdikogianni, MD, Maria Kalmanti, MD, PhD

Blood (2010) 116 (21): 4853.

https://doi.org/10.1182/blood.V116.21.4853.4853

Published: 2010

Journal Articles

Cardiac Safety of One Versus Four Hour Romidepsin (Istodax®) Infusion In the Setting of a Phase I/II Trial of Romidepsin, Dexamethasone and Bortezomib for Relapsed or Refractory Multiple Myeloma

Sam A Ruell, RN, Miles Prince, MD, FRACP, FRCPA, Hang Quach, MBBS, FRACP, FRCPA, MD, Emma Link, PhD, Joanne Dean, Simon J. Harrison, MD, PhD

Blood (2010) 116 (21): 5037.

https://doi.org/10.1182/blood.V116.21.5037.5037

Published: 2010

Journal Articles

Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.

Christopher Cabell, M.D., M.H.S., F.A.C.C., Susan Bates, MD, Richard Piekarz, MD, PhD, Sean Whittaker, MD, FRCP, Youn H Kim, MD, Michelle Currie, C. J Godfrey, Ph.D., Christopher Schoonmaker, Ph.D., Jean Nichols, PhD, Darrell Nix, Ph.D., Howard A. Burris, MD

Blood (2009) 114 (22): 3709.

https://doi.org/10.1182/blood.V114.22.3709.3709

Published: 2009

Journal Articles

Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).

Ruben Niesvizky, MD, Scott Ely, MD, MPH, Maurizio DiLiberto, PhD, Hearn J. Cho, MD, PhD, Udi Y. Gelbshtein, David S. Jayabalan, Sangeeta Aggarwal, MD, Janice L. Gabrilove, MD, Roger N. Pearse, MD, PhD, Karen Pekle, RN, ANPC, Faiza Zafar, RPAC, Zoe Goldberg, MD, John P. Leonard, MD, John J. Wright, MD, Selina Chen-Kiang, PhD, Morton Coleman, MD

Blood (2005) 106 (11): 2574.

https://doi.org/10.1182/blood.V106.11.2574.2574

Published: 2005

NARROW

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the United States

Concomitant Acute Promyelocytic Leukemia and Chronic Lymphocytic Leukemia: Molecularly Two Distinct Diseases

Two Cases of Pediatric Acute Lymphoblastic Leukemia with t(5;14): a Challenging and Unique Entity

Cardiac Safety of NEPA, a Fixed-Dose Antiemetic Combination, Administered Prior to Anthracycline-Based Chemotherapy

Comparative Effectiveness and Safety Of Pathogen Inactivated (Amotosalen-UVA) and Conventional Plasma For Treatment Of Auto-Immmune Thrombotic Thrombocytopenic Purpura (TTP): A 15-Year Retrospective Review

Evaluation of the Acute Coronary Syndrome Safety Profile of Dabigatran Etexilate in Patients Undergoing Major Orthopaedic Surgery: Findings From Four Phase III Trials

Comparison of Adverse Drug Reactions for Patients Treated with Tyrosine Kinase Inhibitors: Data Mining of the Public Version of the FDA Adverse Event Reporting System (AERS)

Fas and Fas Ligand Expression In Children with Acute Lymphoblastic Leukemia, Benign Hematological Diseases and Solid Tumors

Cardiac Safety of One Versus Four Hour Romidepsin (Istodax®) Infusion In the Setting of a Phase I/II Trial of Romidepsin, Dexamethasone and Bortezomib for Relapsed or Refractory Multiple Myeloma

Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.

Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only